According to Sinopharm Hyundai's announcement, Sinopharm Group Chuankang Pharmaceutical Co., Ltd., a holding subsidiary of the company, has received the “Drug GMP Compliance Inspection Notice” issued by the Sichuan Drug Administration. The newly launched API production line after the transformation complies with the “Pharmaceutical Production Quality Management Code” and related appendices, and the production capacity of the production line is 100 kg/year. Passing this inspection will help the company expand the scale of API production capacity in the immunosuppressant sector, and will not have a significant impact on the company's current business performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.